DermaSensor Data, Analytics & Interoperability: Features, Pricing & Alternatives
FDA-cleared AI handheld device for adjunctive skin cancer risk assessment
DermaSensor offers the only FDA-cleared, AI-powered, non-invasive device for automated skin cancer detection in clinical practice.
Our take
DermaSensor is best suited for Primary care, family medicine, and other non-dermatology clinicians who need adjunctive, point-of-care risk assessment for suspicious skin lesions. First FDA-cleared automated adjunctive device for skin cancer risk assessment.
Main limitation: adjunctive only — cannot be used to rule in or rule out cancer on its own. Scored 3.3/5 across the EHRAtlas scorecard.
DermaSensor Overview
DermaSensor is a Miami-based medical device company whose flagship product is a handheld, non-invasive skin cancer risk assessment device cleared by the FDA in January 2024 as a Class II Skin Lesion Analyzer. The device shines light into a suspicious lesion and analyzes the backscattered signal using Elastic Scattering Spectroscopy (ESS), then applies a locked, non-adaptive AI algorithm to return an immediate "Investigate Further" or "Monitor" result with a similarity score.
It is explicitly positioned as an adjunctive tool for physicians who are not dermatologists — primary care, family medicine, internal medicine, and value-based care clinicians — rather than a replacement for dermatologic expertise or biopsy. The company has published validation data including high sensitivity for melanoma, basal cell carcinoma, and squamous cell carcinoma, and reports adoption across hundreds of healthcare institutions.
DermaSensor is not an EHR, RCM, or telehealth platform. It is a point-of-care diagnostic device sold with clinician education (DermaSensor Academy), a customer portal, and reimbursement navigation services through The Reimbursement Group. Its closest analogues are other AI-assisted diagnostic devices rather than software suites.
Reported scale: 51,652 suspicious lesions scanned; 8,161 skin cancers detected to date; Adopted across hundreds of healthcare institutions.
Latest DermaSensor News
DermaSensor Evaluation
Scored against the same 7 dimensions used in the EHRAtlas Scorecard. 0 = not enough public information to score. These are analyst estimates, not endorsements — verify during a demo. Buyers should validate capabilities, pricing, implementation requirements, and fit during vendor evaluation.
Age, customer base, feature depth.
FDA cleared in early 2024 after a long development and clinical study period; the company reports adoption across hundreds of institutions and has continued to publish validation data and expand internationally, though the installed base is still small relative to established diagnostic device categories.
Solo/small, mid, enterprise, or niche.
Deliberately aimed at non-dermatologist physicians — primary care, family medicine, internal medicine, and value-based care organizations — a large and underserved segment. Health systems and dermatology practices are secondary audiences.
What sets it apart from alternatives.
First and, as of the mid-2020s, only FDA-cleared automated device for adjunctive skin cancer risk assessment. ESS plus a locked AI algorithm probes sub-cellular features that visual and dermoscopic exam cannot, and the result is delivered in minutes at the point of care.
Systems it connects to out of the box.
No EHR, lab, billing, or HIE integrations are documented. The device is standalone; results are typically documented manually in the chart, which limits workflow automation for health systems.
HIPAA, SOC 2, ONC, FDA, other.
FDA Class II clearance (2024) is the key regulatory milestone, with a Class IIb CE Mark and NHS collaboration announced for international expansion. HIPAA and SOC 2 posture is not publicly documented, and the product is not ONC-certified (it is not EHR software).
In-house vs outsourced, SLAs, channels.
Structured onboarding via virtual training, a self-paced DermaSensor Academy curriculum, a customer portal knowledge base, and live specialist support. Reimbursement guidance is delivered through a partnership with The Reimbursement Group, which is unusual and valuable for a device of this type.
How it charges and what the entry point is.
No public list price, subscription, or per-use fee is disclosed. Sales are demo-and-quote, and the economics depend heavily on whether payers reimburse the associated CPT code, which the company supports but does not guarantee.
DermaSensor Pricing
| Practice Size | Monthly (per provider) | Implementation | Notes |
|---|---|---|---|
| Solo | Contact vendor | Contact vendor | No public pricing; demo and sales contact required. Economics depend on payer reimbursement for the associated skin lesion analysis code. |
| Small | Contact vendor | Contact vendor | No public pricing. Reimbursement navigation support is included via The Reimbursement Group. |
| Mid | Contact vendor | Contact vendor | No public pricing. Multi-site practices typically negotiate device fleet and training bundles directly. |
| Enterprise | Contact vendor | Contact vendor | No public pricing. Health system and value-based care deployments are referenced but contract terms are not disclosed. |
Pricing is indicative. Always request a formal quote and ask about module, interface, and annual maintenance fees.
Key Features
AI-powered lesion assessment
Elastic Scattering Spectroscopy captures sub-cellular optical signatures, and a locked, non-adaptive AI algorithm classifies the lesion without learning drift over time.
Immediate point-of-care result
Returns an "Investigate Further" or "Monitor" recommendation with a similarity score in minutes, supporting same-visit decisions.
Adjunctive clinical decision support
Explicitly designed to supplement, not replace, physician judgment for melanoma, basal cell carcinoma, and squamous cell carcinoma.
Clinician education program
Virtual onboarding, DermaSensor Academy e-learning modules, and a customer portal knowledge base for non-dermatologist users.
Reimbursement navigation
Coding guidance, payer documentation support, and a provider hotline delivered through The Reimbursement Group partnership.
Fit
Specialties Served
Integrations & Compliance
Capabilities
Systems It Connects To
- billing
- hie
- lab-int
Compliance
| Item | Status | Note |
|---|---|---|
| ONC Certified Health IT | No | Not listed in the ONC CHPL active database. |
| FDA cleared | Yes | Cleared in January 2024 as a Class II Skin Lesion Analyzer for lesions suggestive of melanoma, basal cell carcinoma, and squamous cell carcinoma. |
| CE Mark | Yes | Class IIb CE Mark announced in 2026 alongside an NHS collaboration, enabling European commercialization. |
| HIPAA | Not published | No public HIPAA compliance statement; the device handles limited patient data, but no BAA or privacy documentation is published. |
| SOC 2 | Not published | No public SOC 2 report or equivalent security attestation. |
DermaSensor Pros & Cons
Pros
- First FDA-cleared automated adjunctive device for skin cancer risk assessment
- Non-invasive, minutes-long point-of-care result that fits a primary care visit
- Purpose-built for non-dermatologist clinicians, addressing a real access gap
- Reimbursement navigation included through The Reimbursement Group
- Structured clinician education via DermaSensor Academy and onboarding
Cons
- Adjunctive only — cannot be used to rule in or rule out cancer on its own
- No public pricing; ROI depends on payer reimbursement for the associated code
- No documented EHR, lab, or HIE integrations, so results are charted manually
- Requires a physical handheld device and per-exam consumable workflow
- HIPAA and SOC 2 posture not publicly documented
DermTech
Non-invasive skin cancer assessment via genomic analysis of adhesive patch samples rather than optical spectroscopy; different workflow and evidence base.
SkinVision
Smartphone-based lesion assessment app aimed at consumers and some clinicians; not FDA cleared for the same adjunctive indication.
Canfield Scientific
Dermatology imaging and documentation systems used in specialty practices, complementary rather than directly competitive.
Compare DermaSensor vs Canfield Scientific →Explore EHR Software Ecosystem: Integrations, Partners & Add-Ons Compare DermaSensor with other Dermatology and Internal EHR vendors or browse the full EHR & Healthcare Technology Solutions Index.
Are you DermaSensor? Claim your vendor profile, add product details, and reach practices researching EHRs. Claim Profile/Get Listed
Spotted an error? We publish this data as-is from CMS sources. If a practice or vendor listing is wrong, email support@ehratlas.com and we'll review it.
About This Data & Methodology
Source: This profile is assembled from the vendor's public website (features, capabilities, customer stories, media, and product updates) and EHRAtlas analyst evaluation. Compliance claims, pricing, and integration details should be verified directly with the vendor before making a purchase decision.
Methodology: Where available, we extract structured facts (customers, outcomes, integrations, security certifications) directly from the vendor's own published pages. Claims are linked to their source. Scores reflect analyst judgment based on available public evidence and are not endorsements.
Updates: Vendors are re-scanned periodically. Profile last reviewed on the date shown in the hero.
Corrections: If you spot an error or a change in the vendor's product, capabilities, or pricing, email us and we'll review it.
Spotted an error or need to submit a correction? Email support@ehratlas.com.